GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Cyclically Adjusted PB Ratio

Medigen Biotechnology (ROCO:3176) Cyclically Adjusted PB Ratio : 2.42 (As of Jun. 05, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Cyclically Adjusted PB Ratio?

As of today (2024-06-05), Medigen Biotechnology's current share price is NT$43.70. Medigen Biotechnology's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was NT$18.03. Medigen Biotechnology's Cyclically Adjusted PB Ratio for today is 2.42.

The historical rank and industry rank for Medigen Biotechnology's Cyclically Adjusted PB Ratio or its related term are showing as below:

ROCO:3176' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.57   Med: 3.29   Max: 6.38
Current: 2.39

During the past years, Medigen Biotechnology's highest Cyclically Adjusted PB Ratio was 6.38. The lowest was 1.57. And the median was 3.29.

ROCO:3176's Cyclically Adjusted PB Ratio is ranked worse than
59.39% of 660 companies
in the Biotechnology industry
Industry Median: 1.745 vs ROCO:3176: 2.39

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Medigen Biotechnology's adjusted book value per share data for the three months ended in Mar. 2024 was NT$11.174. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$18.03 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Medigen Biotechnology Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Medigen Biotechnology's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Cyclically Adjusted PB Ratio Chart

Medigen Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.98 3.82 3.33 1.81 2.46

Medigen Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.73 1.76 1.81 2.46 2.15

Competitive Comparison of Medigen Biotechnology's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Medigen Biotechnology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Biotechnology's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Medigen Biotechnology's Cyclically Adjusted PB Ratio falls into.



Medigen Biotechnology Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Medigen Biotechnology's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=43.70/18.03
=2.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Biotechnology's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Medigen Biotechnology's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=11.174/131.7762*131.7762
=11.174

Current CPI (Mar. 2024) = 131.7762.

Medigen Biotechnology Quarterly Data

Book Value per Share CPI Adj_Book
201406 22.822 100.560 29.907
201409 21.717 100.428 28.496
201412 20.814 99.070 27.685
201503 19.870 99.621 26.284
201506 19.272 100.684 25.223
201509 18.772 100.392 24.641
201512 17.984 99.792 23.748
201603 18.289 100.470 23.988
201606 17.271 101.688 22.381
201609 16.647 101.861 21.536
201612 15.873 101.863 20.534
201703 15.095 102.862 19.338
201706 14.451 103.349 18.426
201709 14.328 104.136 18.131
201712 13.249 104.011 16.786
201803 12.949 105.290 16.206
201806 13.186 106.317 16.344
201809 12.472 106.507 15.431
201812 11.084 105.998 13.780
201903 10.902 107.251 13.395
201906 11.430 108.070 13.937
201909 10.798 108.329 13.135
201912 9.793 108.420 11.903
202003 9.819 108.902 11.881
202006 9.705 108.767 11.758
202009 10.349 109.815 12.419
202012 13.062 109.897 15.663
202103 13.595 111.754 16.031
202106 14.084 114.631 16.190
202109 15.420 115.734 17.557
202112 17.181 117.630 19.247
202203 17.775 121.301 19.310
202206 18.106 125.017 19.085
202209 18.239 125.227 19.193
202212 15.734 125.222 16.558
202303 14.133 127.348 14.624
202306 13.634 128.729 13.957
202309 13.377 129.860 13.574
202312 11.422 129.419 11.630
202403 11.174 131.776 11.174

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Medigen Biotechnology  (ROCO:3176) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Medigen Biotechnology Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigen Biotechnology (ROCO:3176) Business Description

Traded in Other Exchanges
N/A
Address
Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.

Medigen Biotechnology (ROCO:3176) Headlines

No Headlines